Work

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.3020

Authors: Alexander E. Drilon, Melissa Lynne Johnson, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Marzieh Golmakani, Micaela Reddy, Allison Harney, Colleen Oliver, Bethany Mills, Judy Therond, S. Michael Rothenberg, Manish Sharma, Timothy A. Yap

Institutions: Memorial Sloan Kettering Cancer Center, Sarah Cannon, Henry Ford Health, Henry Ford Hospital, Pfizer (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Protein Tyrosine Phosphatases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4379283324

Cites:

Cited by: 8

Related to: 10